An orally available, highly selective 5-hydroxytryptamine 2B (5-HT2B) receptor antagonist ameliorating pulmonary and dermal fibrosis Source: International Congress 2019 – New mechanistic insights into pulmonary fibrosis Year: 2019
Vasopressin is involved in endothelin receptor antagonist-induced fluid retention in rat. Differential effect of selective ETA and dual ETA/ETB receptor antagonists Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012
The dual endothelin receptor antagonist bosentan reduces TNFα induced GM-CSF release more effectively than the endothelin A receptor antagonist ambrisentan Source: Annual Congress 2010 - Airway smooth muscle cells Year: 2010
Novel triple neurokinin receptors antagonist CS-003 strongly inhibits neurokinin related responses Source: Eur Respir J 2006; 28: Suppl. 50, 115s Year: 2006
Overexpression of serotonin receptor 1B (5HT-1B) responsible for overflow induced experimental pulmonary arterial hypertension development Source: Annual Congress 2003 - Pathophysiology of the pulmonary circulation Year: 2003
Pharmacological activities of R-113281, a triple NK1 /NK2 /NK3 neurokinin receptor antagonist Source: Eur Respir J 2001; 18: Suppl. 33, 264s Year: 2001
Unique receptor dissociation kinetics of the novel endothelin receptor antagonist macitentan Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012
Selective YAP/TAZ inhibition in fibroblasts via dopamine receptor D1 agonism reverses fibrosis Source: International Congress 2019 – Damage and remodelling in pulmonary fibrosis Year: 2019
One component of the antigen-induced contraction of the guinea-pig trachea is mediated by serotonin acting on 5-HT2A receptors Source: Eur Respir J 2007; 30: Suppl. 51, 620s Year: 2007
The novel dual D2 dopamine receptor, β2 -adrenoceptor agonist Viozan™ (AR-C68397AA) is well tolerated in a dog model Source: Eur Respir J 2001; 18: Suppl. 33, 406s Year: 2001
In vitro pharmacological profile of CHF 5407, a potent, long-acting and selective muscarinic M3 receptor antagonistSource: Eur Respir J 2007; 30: Suppl. 51, 25s Year: 2007
Modulation of cortical and respiratory activity by 5-HT2 receptor agonist in the rat Source: Annual Congress 2008 - Control of breathing and respiratory disorders during sleep Year: 2008
Selective versus non-selective endothelin receptor antagonists Source: Annual Congress 2005 - New treatments in pulmonary hypertension Year: 2005
Effect of AVE5883, a dual NK1/NK2 receptor antagonist, on airway responsiveness to neurokinin A in asthma Source: Eur Respir J 2004; 24: Suppl. 48, 219s Year: 2004
Tachykinin 1 receptor antagonist FK888 suppresses angiotensin converting enzyme inhibitors (ACEIs)-induced tracheal inflammation, an experimental study Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013
In vivo potent and long-lasting bronchodilator activity of muscarinic M3 receptor antagonist CHF5407Source: Eur Respir J 2007; 30: Suppl. 51, 26s Year: 2007
Potential role of memantine in the prevention and treatment of COVID-19: its antagonism of nicotinic acetylcholine receptors and beyond Source: Eur Respir J, 56 (2) 2001610; 10.1183/13993003.01610-2020 Year: 2020
The endocannabinoids anandamide and 2-arachidonyl-glycerol (2-AG) induce pulmonary hypertension (PH) in a CB1 receptor independent manner - role of COX-2 and EP1 receptor activation Source: Eur Respir J 2005; 26: Suppl. 49, 733s Year: 2005
Dual endothelin receptor antagonism: setting standards in PAH Source: Eur Respir Rev 2008; 17: 13-18 Year: 2007
Aclidinium bromide, a novel muscarinic receptor antagonist combining long residence at M3 receptors and rapid plasma clearance Source: Annual Congress 2007 - New drugs for COPD Year: 2007